CURRENT PHARMACOTHERAPY FOR SYSTEMIC JUVENILE ARTHRITIS
Systemic juvenile arthritis (sJA) is one of the severest childhood somatic diseases. The relevance of the problem associated with sJA is determined by difficulties in early diagnosis, by the rapid development of disability, and by poor prognosis with a high risk for life-threatening conditions. It s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2043 |
| Summary: | Systemic juvenile arthritis (sJA) is one of the severest childhood somatic diseases. The relevance of the problem associated with sJA is determined by difficulties in early diagnosis, by the rapid development of disability, and by poor prognosis with a high risk for life-threatening conditions. It still persists despite the fact that a notable advance has been made in pharmacotherapy, which could substantially change the prognosis of sJA. The use of disease-modifying anti-rheumatic drugs (DMARDs) and then the advent of biological agents (BAs) have fundamentally changed the drug regimen for the treatment of sJA. The paper considers the aspects of using different DMARDs and BAs in sJA in the context of evidence-based medicine, by analyzing the data available in the literature. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |